NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization
NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization
PARAMUS, N.J., July 10, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced that its Board of Directors has appointed a new President at its US headquarters. Yukiteru Sugiyama, Ph.D. replaces retiring president Tsugio Tanaka, MSc as of June 30, 2024.
2024年7月10日，尼普順藥業有限公司（Nippon Shinyaku）下屬子公司NS Pharma, Inc.（NS Pharma）宣佈，其董事會已經任命新總裁負責該公司的美國總部。博士Yukiteru Sugiyama取代退休的Tsugio Tanaka，MSc，自2024年6月30日起。
"As president, it is my mission to maintain heightened levels of empathy at NS Pharma."
“作爲總裁，我致力於在NS Pharma保持更高程度的同情心。”
Sugiyama received a doctorate degree in organic chemistry from Nagoya University in 1996. From 1996 until 2007, he worked in research and clinical development with Nippon Shinyaku in Japan, focusing on structural chemistry and blood cancer therapies. In 2007, he transitioned to the commercial division within the company.
1996年，Sugiyama在名古屋大學獲得有機化學博士學位。從1996年到2007年，他在尼普順藥業工作，專注於結構化學和血液癌症治療的研究和臨床開發。2007年，他轉到了公司的商業部門。
In 2020, during the COVID-19 pandemic, Sugiyama transferred to NS Pharma in the US to work as assistant vice president overseeing commercial functions for VILTEPSO(viltolarsen). In total, Sugiyama has worked for 28 years at Nippon Shinyaku with progressive levels of responsibility.
2020年新冠疫情期間，杉山調任至NS Pharma任職副總裁，負責VILTEPSO（viltolarsen）的商業職能監督。總體上，杉山在日本新藥工業已工作了28年，業務範圍不斷拓展。
"Having served in both our science and patient focused fields, I have come to understand that having empathy for the patient is critical in the development of therapies to treat rare diseases," Sugiyama explained. "As president, it is my mission to maintain heightened levels of empathy at NS Pharma, and to enhance transparency between all stakeholders."
Sugiyama解釋說：“在我們的科學和以患者爲中心的領域任職之後，我明白同情病人對於開發治療罕見病是至關重要的。作爲總裁，我的使命是在NS Pharma保持更高的同情心水平，並增強所有利益相關者之間的透明度。”
Sugiyama will lead the company through the next phases of clinical and commercial development for VILTEPSO and CAP-1002 (through a partnership with Capricor Therapeutics) – for the treatment of Duchenne muscular dystrophy (Duchenne). NS Pharma is also currently working on an exon 44 skipping therapy (Phase 2) and an exon 50 skipping therapy (Phase 1/2) for Duchenne, a selective JAK1 inhibition therapy for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), as well as several preclinical neurological therapies.
Sugiyama將領導公司在VILTEPSO和CAP-1002（與Capricor Therapeutics合作）方面的臨床和商業發展的下一個階段——治療肌萎縮性側索硬化症（Duchenne）。NS Pharma目前正在進行外顯子44跳過療法（第2階段）和外顯子50跳過療法（第1/2階段）的Duchenne治療，以及選擇性JAK1抑制劑治療嗜酸性粒細胞肉芽腫性多血管炎（EGPA）的幾種臨床前神經疾病治療。
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. For more information, please visit nspharma.com.
關於NS Pharma, Inc.
NS Pharma, Inc.是尼普順藥業有限公司（Nippon Shinyaku Co.，Ltd）的全資子公司。NS Pharma是尼普順藥業有限公司的註冊商標。欲了解更多信息，請訪問nspharma.com。
US Media Contact:
[email protected]
美國媒體聯絡:
[email protected]
SOURCE NS Pharma, Inc.
消息來源: NS Pharma, Inc.